Resmed Inc (RMD)
Sous-évaluéFondamental
75
Prix
$219.15
Capitalisation boursière
$32.04B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$5.65B
12 derniers mois (au 30/06/2026)
Résultat net
$1.52B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$1.65B
Capitaux propres totaux
$6.59B
Passif total
$2.38B
Ratio de liquidité général
3.10
Couverture des intérêts
-
Dette/EBITDA
0.40
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$347.54
Prix actuel
$219.15
Marge de sécurité
+36.9%
Fourchette de juste valeur
$225.90 - $469.18
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
21.20
ROE
23.1%
Ratio P/B
4.84
P/FCF
19.34
Marge brute
61.1%
ROIC
19.7%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
19.7%
WACC
8.5%
ROIC − WACC
+11.2 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (19)
- EPS shows upward trend
- EPS CAGR 15.14%
- Price CAGR 13.41%
- ROIC 19.7%
- Gross Margin 61.1%
- P/FCF 19.34
- Debt/Equity ratio
- Operating Margin 33.4%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 23.9%
- Revenue Growth 5Y 12.1%
- PEG Ratio 0.79
- Earnings Quality (OCF/NI) 1.19
- Share Dilution -0.8%
- Piotroski F-Score 7/9
Échoué (7)
- P/B Ratio 4.84
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 48% Buy
- Earnings Surprise avg 0.8%
- Net Margin Trend 26.9% vs 27.2%
Indisponible (2)
- Dividend Payout NaN%
- Interest Coverage
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 53 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 83 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 67 |
| Mr. Brett A. Sandercock | Advisor | 58 |
| Mr. Justin Leong | Chief Product Officer | 47 |
| Mr. Aaron Bloomer | Chief Financial Officer | 39 |
| Mr. Alastair Robertson | Chief Information Officer | - |
| Ms. Sallilyn Schwartz | Chief Investor Relations Officer | - |
| Mr. Jim Ellis | Chief Compliance Officer | - |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 49 |
Risque d'audit
1
Risque du conseil
7
Risque de rémunération
4
Risque droits des actionnaires
3
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-08-13
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-05-01
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-01
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for RMD, sourced from Markets Gazette.
- 3/10/2026POSITIVE3 Reasons Not to Sleep on ResMed Stock
ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.
- 3/4/2026POSITIVEHere's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.
via Markets Gazette